Pharmaceutical industry's perspective on health technology assessment.
This article presents the pharmaceutical industry's perspective on health technology assessment (HTA) with specific comments on the HTA systems in England and Wales, France, The Netherlands, and Sweden. The comments are focused on the following main themes: (i) The contributions of the HTA system to overall efficiency in the health-care system, (ii) HTA as a cost-driver for industry, patients, government, and society, and (iii) The various implementation barriers that currently exist for a successful implementation of HTA results.
Lothgren
Mickael
M
Ratcliffe
Mark
M
D003362:Cost-Benefit Analysis; D004059:Diffusion of Innovation; D004345:Drug Industry; D005060:Europe; D013548:Sweden; D013673:Technology Assessment, Biomedical; D006113:United Kingdom